Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.

Autor: Chai KL; a Department of Hematology , St Vincent's Hospital , Melbourne , Australia., Rowan G; b Department of Pharmacy , Peter MacCallum Cancer Centre , Melbourne , Australia., Seymour JF; c Department of Hematology , Peter MacCallum Cancer Centre , Melbourne , Australia.; d Department of Medicine, University of Melbourne , Parkville , Victoria , Australia., Burbury K; c Department of Hematology , Peter MacCallum Cancer Centre , Melbourne , Australia., Carney D; c Department of Hematology , Peter MacCallum Cancer Centre , Melbourne , Australia.; d Department of Medicine, University of Melbourne , Parkville , Victoria , Australia., Tam CS; a Department of Hematology , St Vincent's Hospital , Melbourne , Australia.; c Department of Hematology , Peter MacCallum Cancer Centre , Melbourne , Australia.; d Department of Medicine, University of Melbourne , Parkville , Victoria , Australia.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2017 Dec; Vol. 58 (12), pp. 2811-2814. Date of Electronic Publication: 2017 May 15.
DOI: 10.1080/10428194.2017.1315115
Abstrakt: The management of AF represents a major challenge in patients with CLL, especially in elderly patients with multiple comorbidities who are representative of the majority of patients with CLL. This is especially complex in the case of ibrutinib. Many anticoagulants have potential for pharmacological interaction with ibrutinib, and ibrutinib itself has antiplatelet properties. Use of ibrutinib therapy in these patients mandates review and revision of the need for anticoagulation and best anticoagulant to use. Herein, we review the current knowledge of the metabolism of common anticoagulants and how they may interact with ibrutinib.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje